Facilities Expansion
October 2018 saw the completion of a 72-bed expansion within formerly shelled space in the 21-story James Cancer Hospital and Solove Research Institute, a project that gives patients greater access to hospital services by increasing the number of cancer and non-cancer critical care and acute medical-surgical care/progressive ICU care beds. Among the new 72 are 48 cancer beds – including 36 acute care beds and 12 critical care beds – raising the total number of beds at The James from 308 to 356. (The other 24 new beds within the formerly shelled space are for non-cancer critical care patients treated at Ohio State Wexner Medical Center.)
Patient Care
In fiscal year 2018, the OSUCCC – James treated nearly 15,000 inpatients, received more than 430,000 outpatient visits and had a general inpatient occupancy rate of over 91 percent. To accommodate growth in patient volume, the institution hired some 250 new faculty and staff in fiscal year 2018.
Clinical Trials
Patients at the OSUCCC – James have access to hundreds of clinical trials that offer some of the most sophisticated treatments available anywhere, including some that are available nowhere else. In fiscal year 2018, researchers at the OSUCCC – James opened 129 clinical trials to bring the total number of available trials to more than 900, of which approximately 450 are interventional. The five-year average patient accrual to clinical trials here is 23 percent (nearly one in four patients), well above the national average of three percent.
Total Cancer Care® Protocol
Since 2014, the OSUCCC – James has enrolled nearly 47,000 patients (including 10,000 in the past year for a 94 percent accrual rate) in a Total Cancer Care® (TCC) protocol for voluntarily sharing de-identified clinical data that helps move cancer research forward and personalizes cancer care. The TCC protocol helps clinicians understand differences among cancer patients and find ways to individualize prevention, detection and treatment.
ORIEN Precision Medicine Collaboration
The TCC protocol referenced above has been adopted by all 19 member institutions across the nation that constitute the Oncology Research Information Exchange Network (ORIEN), a research collaboration that was co-founded and is co-anchored by the OSUCCC – James and Moffitt Cancer Center in Tampa, Fla. Through ORIEN, more than 200,000 TCC-consented patients from around the country have agreed to donate their clinical data for research to help scientists understand cancer at the molecular level, making ORIEN the world’s largest precision medicine collaboration to address cancer.
Research Grant Funding
The OSUCCC – James has more than 340 cancer researchers who collectively represent 11 of the 15 colleges at Ohio State. Each researcher is a member of one of five multidisciplinary research programs: Cancer Control, Leukemia Research, Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention, and Translational Therapeutics. In fiscal year 2018, OSUCCC – James researchers received 28 new research grants totaling over $30 million from the National Cancer Institute (NCI). The OSUCCC – James ranks 25th among cancer institutions in the United States for total NCI funding.
Research Publications
Medical scientists at the OSUCCC – James frequently publish cancer-related articles in prestigious scientific journals. Nearly 90 percent of the publications are collaborative, meaning that researchers are working and sharing expertise with others outside their labs and often with scientists at other institutions. In 2018, cancer researchers at Ohio State authored or co-authored 750 publications, including 108 in journals with impact factors of 10 or higher. Here are a few examples of 2018 publications in top-rated journals (names in bold are OSUCCC members):
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer With a High Tumor Mutational Burden. New England Journal of Medicine 2018;378:2093-2104. Impact Factor: 79.258
• Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, Klco JM, Helton NM, O’Laughlin M, Fronick CC, Fulton RS, Wilson RK, Wartman LD, Welch JS, Heath SE, Baty JD, Payton JE, Graubert TA, Link DC, Walter MJ, Westervelt P, Ley TJ, DiPersio JF. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine 2018;379:2330-2341. Impact Factor: 79.258
• Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC. Ibrutinib Regimens Versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine 2018;379:2517-2528. Impact Factor: 79.258
• Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. Journal of the American Medical Association 2018;320:469-477. Impact Factor: 47.661
• Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA. Clonal EvoluEion Mechanisms in NT5C2 Mutant-Relapsed Acute Lymphoblastic Leukemia. Nature 2018;553:511-514. Impact Factor: 41.577
• Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. The Genetic Basis and Cell of Origin of Mixed Phenotype Acute Leukemia. Nature 2018;562:373-379. Impact Factor: 41.577
• Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR. EWS-FLI1 Increases Transcription to Cause R-Loops and Block BRCA1 Repair in Ewing Sarcoma. Nature 2018;555:387-391. Impact Factor: 41.577
• Pi F, Binzel DW, Lee TJ, Li Z, Sun M, Rychahou P, Li H, Haque F, Wang S, Croce CM, Guo B, Evers BM, Guo P. Nanoparticle Orientation to Control RNA Loading and Ligand Display on Extracellular Vesicles for Cancer Regression. Nature Nanotechnology 2018; 13:82-89. Impact Factor: 37.49
• Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for Chronic Lymphocytic Leukemia Progressing After Ibrutinib: An Interim Analysis of a Multicenter, Open-Label, Phase 2 Trial. Lancet Oncology 2018;19:65-75.; Impact Factor: 36.418
Drug Development Institute (DDI)
The DDI is a biotech-like institute embedded within the OSUCCC – James that employs a combination of targeted investments, strategic management and cutting-edge resources to drive projects from discovery to early-stage development of drugs for cancer therapy. Led by DDI director and clinical pharmacist Jeffrey Patrick, PharmD, the DDI team works with world-renowned investigators who conduct research in multidisciplinary teams. Among current projects in the DDI pipeline are:
- “Activated B Cells as a Therapeutic Cancer Vaccine Platform”
- “Selective Activation of Immune Cells via the Notch Pathway”
- “Selective RAL A GTPase Inhibitors as a Cancer Treatment”
- “Selective Estrogen Receptor Modulator (ER-β Agonist) as a New Approach to Targeting Cancer”
- “Split Delivery and Functional Reconstruction of Immunotoxins via Dual Tumor-Targeted Pathways”
- “Mps1 Kinase Inhibitor as a Treatment for Solid Tumors”
- “PP2A Activator for Treatment of AML and Other Hematologic Malignancies”
- “Aryl Hydrocarbon Receptor as a Target for Multiple Myeloma”